$GILD.TSX Q2 '26 Earnings Results & Recap
Gilead Sciences now expects full year 2026 product sales between $30.1 billion and $30.4 billion, with GAAP diluted loss per share between $(3.75) and $(3.40) and non-GAAP diluted loss per share between $(0.65) and $(0.30).